Charles River Laboratories International has announced new and continuing collaborations with three innovative drug discovery partners funded by the Wellcome Trust. Antabio, an antibacterial drug discovery company; Pcovery, a spin-out company focused on anti-fungals; and the British Columbia Cancer Agency have all extended existing or commenced new agreements with Charles River’s Global Discovery Services business.

“We are delighted Antabio, Pcovery and the British Columbia Cancer Agency selected Charles River as their partner for the Wellcome Trust’s Seeding Drug Discovery (SDD)-funded programs,” said Emily Hickey, corporate senior vice president of global discovery services at Charles River.

As part of the agreements, Charles River’s Discovery Business will provide a comprehensive suite of in vitro and in vivopharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services.